Entera Bio Ltd. financial data

Symbol
ENTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Kiryat Hadassah, Minrav Building, Fifth Floor, Jerusalem, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 758 % +21.4%
Debt-to-equity 17.2 % -19.5%
Return On Equity -120 % -17.4%
Return On Assets -102 % -21.6%
Operating Margin -71.4K % -1350%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 45.4M shares +28%
Common Stock, Shares, Outstanding 38.8M shares +9.47%
Entity Public Float 58.8M USD +184%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 37.7M shares +29.8%
Weighted Average Number of Shares Outstanding, Diluted 37.7M shares +29.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 42K USD
Cost of Revenue 42K USD
Research and Development Expense 4.5M USD -0.24%
General and Administrative Expense 5.1M USD +15%
Operating Income (Loss) -9.59M USD -7.81%
Nonoperating Income (Expense) 58K USD +87.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.02M USD -28.6%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -9.54M USD -7.34%
Earnings Per Share, Basic 0.25 USD/shares -19.4%
Earnings Per Share, Diluted 0.25 USD/shares -19.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.66M USD -21.4%
Accounts Receivable, after Allowance for Credit Loss, Current 126K USD
Other Assets, Current 186K USD -21.8%
Assets, Current 8.97M USD -20.3%
Deferred Income Tax Assets, Net 0 USD -100%
Property, Plant and Equipment, Net 57K USD -43%
Operating Lease, Right-of-Use Asset 275K USD -29.1%
Assets 9.39M USD -20.2%
Accounts Payable, Current 132K USD +59%
Liabilities, Current 1.18M USD +7.79%
Operating Lease, Liability, Noncurrent 102K USD -60.2%
Liabilities 1.31M USD -5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 41K USD 0%
Retained Earnings (Accumulated Deficit) -114M USD -9.14%
Stockholders' Equity Attributable to Parent 8.08M USD -22.2%
Liabilities and Equity 9.39M USD -20.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.86M USD -15.7%
Net Cash Provided by (Used in) Financing Activities 30K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 140M shares 0%
Common Stock, Shares, Issued 38.8M shares +9.47%
Common Stock, Par or Stated Value Per Share 0 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.83M USD -13.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.74M USD -21.2%
Deferred Tax Assets, Valuation Allowance 20.9M USD +7.2%
Deferred Tax Assets, Gross 20.9M USD +7.12%
Operating Lease, Liability 272K USD -30.3%
Depreciation 13K USD -7.14%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 301K USD -33.7%
Operating Lease, Liability, Current 170K USD +26.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 101K USD -45.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 198K USD +7.61%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29K USD -54.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2K USD -97.7%
Deferred Tax Assets, Operating Loss Carryforwards 19.2M USD +10.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 83K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%